New drug ARGX-109 tested for safety in first human trial
NCT ID NCT06799416
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed Phase 1 trial tested a single dose of ARGX-109 in 40 healthy adults to see if it is safe and how the body processes it. Participants were randomly assigned to receive either the drug or a placebo. The study lasted about 20 weeks and focused on side effects and drug levels in the blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ARGX-109
What this could lead to
If successful, this could pave the way for testing ARGX-109 in people with diseases linked to inflammation.
What could go wrong
This is an early, small study in healthy people, so it cannot show if ARGX-109 works for any disease. Side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Altasciences - Montreal - Phase I unit
Mount Royal, Quebec, H3P 3P1, Canada